Docoh
Loading...

VBLT Vascular Biogenics

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL's lead oncology product candidate, ofranergene obadenovec (VB-111), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VB-111 is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.

VBLT stock data

(
)

Calendar

25 Mar 21
23 Oct 21
31 Dec 21
Quarter (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

6.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 24 26 -7.7%
Opened positions 6 12 -50.0%
Closed positions 8 5 +60.0%
Increased positions 5 4 +25.0%
Reduced positions 4 4
13F shares
Current Prev Q Change
Total value 38.18M 58.7M -35.0%
Total shares 3.83M 2.69M +42.4%
Total puts 61.2K 25.8K +137.2%
Total calls 253.5K 388.2K -34.7%
Total put/call ratio 0.2 0.1 +263.3%
Largest owners
Shares Value Change
PXGPE Phoenix 1.06M $2.53M NEW
Ikarian Capital 800.81K $1.92M 0.0%
MS Morgan Stanley 693.42K $1.66M -4.2%
DAFNA Capital Management 306.98K $734K NEW
MCQEF Macquarie 200K $478K 0.0%
Telemetry Investments, L.L.C. 152.76K $365K +42.1%
Citadel Advisors 126.65K $303K NEW
LPLA LPL Financial 101.18K $242K +110.8%
Boothbay Fund Management 89.69K $214K 0.0%
Group One Trading 41.15K $98K +418.9%
Largest transactions
Shares Bought/sold Change
PXGPE Phoenix 1.06M +1.06M NEW
DAFNA Capital Management 306.98K +306.98K NEW
California Public Employees Retirement System 0 -248.16K EXIT
Citadel Advisors 126.65K +126.65K NEW
Squarepoint Ops 27.13K -87.28K -76.3%
Renaissance Technologies 0 -75.8K EXIT
LPLA LPL Financial 101.18K +53.18K +110.8%
Telemetry Investments, L.L.C. 152.76K +45.26K +42.1%
VIRT Virtu Financial 39.62K +39.62K NEW
Millennium Management 37.16K +37.16K NEW

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Abs, accommodate, Antonio, Ark, ASC, Aspire, ASU, Austin, BS, buyer, Buyse, career, Casado, category, children, Clin, component, concurrent, concurrently, corroborated, criterion, curbing, cytokine, dataset, Davidson, Delaware, Derech, Dicerna, Digestive, dozen, DRNA, DukeEngage, Endocyte, England, EPO, erosion, EULAR, Exp, FASB, futility, gender, Greenlight, Gynecol, HCR, Herraez, hierarchy, Immunol, Int, intrinsic, isolated, Isr, Jerian, Kozin, lab, League, led, Leo, Library, Madrid, maker, Marc, MBA, mediated, medtech, Menachem, Mereo, moderately, monetization, monthly, morbidity, multiplied, navicixizumab, NJ, online, Overview, pattern, peer, presumption, prominent, PTE, Puglisi, purification, Rainey, reconciling, rescind, rescission, Rheumatism, ROU, Salem, shelf, shifting, Somerset, SPTE, step, storm, Suite, SUPPLEMENTARY, surrender, threshold, TX, UFP, UFPT, UK, unamortized, unblinded, underway, uneven, unreasonable, unregistered, USA, Victor, virtual, water, Wharton, withdrawn, Yacov
Removed: accreted, actuarial, adjusting, Affordable, Alchemia, amortized, approximating, assured, attenuate, augmented, Bayer, Bioscience, Bonnie, broker, bundle, bundled, Burger, Cerulean, circumvented, collection, collusion, compartment, composed, comprising, crucial, CT, Dar, dealer, dealing, defer, emphasized, fatty, faulty, Fax, feasible, forgivable, Fredericka, Goldman, Gonczarowski, greatly, grouped, Hamered, hand, Humphrey, IAS, implicated, infiltrating, Jaffray, Kelley, kidney, Kupffer, lifecycle, lobular, lsr, macrophage, maximize, minimize, mistake, Modiin, mouse, multidisciplinary, murine, Myeloma, noncurrent, oncologist, operated, optimal, outflow, outlined, overwhelming, passage, pathological, Pennsylvania, Pharmacology, Piper, pretax, projected, prone, Prudent, rat, regenerate, remained, remeasurement, resistant, safeguard, scarring, sector, settle, settled, Shekel, signaling, spite, Squibb, strategically, stronger, substantively, technically, termed, Tower, traditionally, training, unconditional, unpredictability, western, worked, Yale

Proxies

No filings

Patents

APP
Utility
Diagnostic Methods for Anti-angiogenic Agent Therapy
21 Oct 21
The disclosure provides methods of treating a tumor in a subject who is capable of exhibiting a change in at least one plasma biomarker or cell surface biomarker after administration of at least one priming dose of a vector which comprises a Fas-chimera gene operably linked to an endothelial cell-specific promoter.
APP
Utility
Motile Sperm Domain Containing Protein 2 and Cancer
1 Apr 21
Disclosed herein are methods of treating, reducing the incidence of, or preventing one or more activities in or of a cancer cell, methods of treating, reducing the incidence of, or preventing migration or metastasis of a cancer cell, methods of treating, reducing the incidence of, or preventing a cancer by reducing tumor associated macrophages (TAMs) or their migration, and methods of treating, reducing the incidence of, or preventing a cancer (including metastatic cancer), for example, with an inhibitor of Motile Sperm Domain containing Protein 2 (MOSPD2).
APP
Utility
Motile Sperm Domain Containing Protein 2 and Inflammation
18 Mar 21
Disclosed herein are methods of treating, preventing, or reducing the incidence of an inflammatory disease or disorder and methods of inhibiting, preventing, or reducing the incidence of one or more activities in a cell with an inhibitor of a Motile Sperm Domain containing Protein 2 (MOSPD2).
APP
Utility
Methods and Compositions for Tumor Radiosensitization
11 Mar 21
Disclosed herein are methods and compositions for radiosensitizing tumor in subjects receiving radiation therapy by administering a gene therapy construct that results in expression of a secretory radiosensitizing agent in tumor endothelium.
APP
Utility
Bispecific Antibodies to MOSPD2 and T Cell- or NK Cell-specific Molecules
30 Dec 20
Disclosed herein are bispecific antibodies or antigen binding fragments thereof that specifically bind to Motile Sperm Domain Containing Protein 2 (MOSPD2) and to a T cell-specific or NK cell-specific receptor molecule, pharmaceutical compositions and kits containing the same, and methods of making and using the same.